Clinical trials: Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on…
- Trial name
- NCT02099110
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 1,233 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus (T2DM)
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
- Trial name
- NCT01514149
- Testing
- CJC-1134-PC Injection
- Where
- 22 sites in United States, Canada
- Volunteers
- 73 people
- Sponsor
- ConjuChem
Diabetes, Diabetes Mellitus, Type 2
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
- Trial name
- NCT03531905
- Testing
- Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet
- Where
- 4 sites in United States
- Volunteers
- 242 people
- Sponsor
- Esperion Therapeutics, Inc.
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease
COORDINATE-Diabetes is a cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level educational intervention to improve the management of patients with type 2 diabetes mellitus and cardiovascular…
- Trial name
- COORDINATE (NCT03936660)
- Testing
- Intense Education Intervention
- Where
- 44 sites in United States
- Volunteers
- 1,049 people
- Sponsor
- Duke University
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
- Trial name
- NCT02737891
- Testing
- Tesofensine/Metoprolol
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Saniona
Type 2 Diabetes
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects.
- Trial name
- NCT03645421
- Testing
- MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg
- Where
- 5 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.
- Trial name
- IMPERIUM (NCT02072096)
- Testing
- Glimepiride, Metformin, Pioglitazone
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or…
- Trial name
- DECLARE-TIMI58 (NCT01730534)
- Testing
- Dapagliflozin 10 mg
- Where
- 805 sites in United States, Argentina and 32 more
- Volunteers
- 17,190 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Coronary Heart Disease
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.
- Trial name
- NCT01588470
- Testing
- pioglitazone
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
The purpose of this study is to assess the safety and efficacy of omarigliptin (MK-3102), dosed once-weekly in participants with T2DM who have inadequate glycemic control on diet and exercise.
- Trial name
- NCT01717313
- Testing
- Omarigliptin, Metformin, Glimepiride
- Volunteers
- 329 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
This study evaluated the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin.
- Trial name
- NCT04029480
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Insulin
- Where
- 104 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks.
- Trial name
- NCT02526524
- Testing
- Met DR, Met IR
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 571 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Hypertension
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker.
- Trial name
- NCT00806585
- Testing
- MK-0736, Comparator: HCTZ
- Volunteers
- 620 people
- Sponsor
- Merck Sharp & Dohme LLC